<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:47:54Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8195366" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8195366</identifier>
        <datestamp>2021-06-21</datestamp>
        <setSpec>plosntd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" xml:lang="en" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS Neglected Tropical Diseases</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1935-2727</issn>
              <issn pub-type="epub">1935-2735</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8195366</article-id>
              <article-id pub-id-type="pmcid">PMC8195366</article-id>
              <article-id pub-id-type="pmc-uid">8195366</article-id>
              <article-id pub-id-type="pmid">34061838</article-id>
              <article-id pub-id-type="pmid">34061838</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pntd.0009361</article-id>
              <article-id pub-id-type="publisher-id">PNTD-D-20-01544</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Parasitic Diseases</subject>
                      <subj-group>
                        <subject>Helminth Infections</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Parasitic Diseases</subject>
                      <subj-group>
                        <subject>Malaria</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Tropical Diseases</subject>
                      <subj-group>
                        <subject>Malaria</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Eukaryota</subject>
                      <subj-group>
                        <subject>Animals</subject>
                        <subj-group>
                          <subject>Invertebrates</subject>
                          <subj-group>
                            <subject>Helminths</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Zoology</subject>
                    <subj-group>
                      <subject>Animals</subject>
                      <subj-group>
                        <subject>Invertebrates</subject>
                        <subj-group>
                          <subject>Helminths</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Eukaryota</subject>
                      <subj-group>
                        <subject>Animals</subject>
                        <subj-group>
                          <subject>Invertebrates</subject>
                          <subj-group>
                            <subject>Helminths</subject>
                            <subj-group>
                              <subject>Schistosoma</subject>
                              <subj-group>
                                <subject>Schistosoma Haematobium</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Zoology</subject>
                    <subj-group>
                      <subject>Animals</subject>
                      <subj-group>
                        <subject>Invertebrates</subject>
                        <subj-group>
                          <subject>Helminths</subject>
                          <subj-group>
                            <subject>Schistosoma</subject>
                            <subj-group>
                              <subject>Schistosoma Haematobium</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Preventive Medicine</subject>
                      <subj-group>
                        <subject>Vaccination and Immunization</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Infectious Disease Control</subject>
                        <subj-group>
                          <subject>Vaccines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Antigens</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System Proteins</subject>
                      <subj-group>
                        <subject>Antigens</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System Proteins</subject>
                      <subj-group>
                        <subject>Antigens</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Proteins</subject>
                      <subj-group>
                        <subject>Immune System Proteins</subject>
                        <subj-group>
                          <subject>Antigens</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Eukaryota</subject>
                      <subj-group>
                        <subject>Protozoans</subject>
                        <subj-group>
                          <subject>Parasitic Protozoans</subject>
                          <subj-group>
                            <subject>Malarial Parasites</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2</article-title>
                <alt-title alt-title-type="running-head">Helminth affect GMZ2 malaria vaccine candidate outcome</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6255-1145</contrib-id>
                  <name>
                    <surname>Nouatin</surname>
                    <given-names>Odilon</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="econtrib001" ref-type="author-notes">
                    <sup>‡</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mengue</surname>
                    <given-names>Juliana Boex</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="econtrib001" ref-type="author-notes">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3816-998X</contrib-id>
                  <name>
                    <surname>Dejon-Agobé</surname>
                    <given-names>Jean Claude</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="econtrib001" ref-type="author-notes">
                    <sup>‡</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4716-0311</contrib-id>
                  <name>
                    <surname>Fendel</surname>
                    <given-names>Rolf</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ibáñez</surname>
                    <given-names>Javier</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ngoa</surname>
                    <given-names>Ulysse Ateba</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1594-9510</contrib-id>
                  <name>
                    <surname>Edoa</surname>
                    <given-names>Jean Ronald</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4208-6212</contrib-id>
                  <name>
                    <surname>Adégbité</surname>
                    <given-names>Bayodé Roméo</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9726-6643</contrib-id>
                  <name>
                    <surname>Honkpéhédji</surname>
                    <given-names>Yabo Josiane</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zinsou</surname>
                    <given-names>Jeannot Fréjus</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hounkpatin</surname>
                    <given-names>Aurore Bouyoukou</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9785-404X</contrib-id>
                  <name>
                    <surname>Moutairou</surname>
                    <given-names>Kabirou</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Homoet</surname>
                    <given-names>Andreas</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Esen</surname>
                    <given-names>Meral</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5025-7221</contrib-id>
                  <name>
                    <surname>Kreidenweiss</surname>
                    <given-names>Andrea</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoffman</surname>
                    <given-names>Stephen L.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Theisen</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="aff010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="aff011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8830-3425</contrib-id>
                  <name>
                    <surname>Luty</surname>
                    <given-names>Adrian J. F.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="aff013" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1427-3002</contrib-id>
                  <name>
                    <surname>Lell</surname>
                    <given-names>Bertrand</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff014" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4693-4207</contrib-id>
                  <name>
                    <surname>Agnandji</surname>
                    <given-names>Selidji Todagbe</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2658-8706</contrib-id>
                  <name>
                    <surname>Mombo-Ngoma</surname>
                    <given-names>Ghyslain</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff015" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9259-1885</contrib-id>
                  <name>
                    <surname>Ramharter</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff015" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kremsner</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9101-2768</contrib-id>
                  <name>
                    <surname>Mordmüller</surname>
                    <given-names>Benjamin</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="aff016" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3197-5946</contrib-id>
                  <name>
                    <surname>Adegnika</surname>
                    <given-names>Ayôla Akim</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Visualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Institut für Tropenmedizin, Universität Tübingen, Tübingen, Germany</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Département de Biochimie et de Biologie Cellulaire, Faculté des Sciences et Techniques, Université d’Abomey-Calavi, Cotonou, Bénin</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam Infection &amp; Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, The Netherlands</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Fondation pour la Recherche Scientifique, Cotonou, Bénin</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Department of Parasitology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>Sanaria, Inc., Rockville, Maryland, United States of America</addr-line>
              </aff>
              <aff id="aff009">
                <label>9</label>
                <addr-line>Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff010">
                <label>10</label>
                <addr-line>Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff011">
                <label>11</label>
                <addr-line>Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark</addr-line>
              </aff>
              <aff id="aff012">
                <label>12</label>
                <addr-line>Centre d’Etude et de Recherche sur le Paludisme Associé à la Grossesse et à l’Enfance, Calavi, Bénin</addr-line>
              </aff>
              <aff id="aff013">
                <label>13</label>
                <addr-line>Université de Paris, MERIT, IRD, Paris, France</addr-line>
              </aff>
              <aff id="aff014">
                <label>14</label>
                <addr-line>Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria</addr-line>
              </aff>
              <aff id="aff015">
                <label>15</label>
                <addr-line>Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine &amp; I, Department of Medicine, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany</addr-line>
              </aff>
              <aff id="aff016">
                <label>16</label>
                <addr-line>Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Röltgen</surname>
                    <given-names>Katharina</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Stanford University, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p>The authors have declared that no competing interests exist.</p>
                </fn>
                <fn fn-type="other" id="econtrib001">
                  <p>‡ These authors contributed equally to the work and share first authorship</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>paterneodilon@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <volume>15</volume>
              <issue>6</issue>
              <elocation-id>e0009361</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>8</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>3</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 Nouatin et al</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Nouatin et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pntd.0009361.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>Helminths can modulate the host immune response to <italic toggle="yes">Plasmodium falciparum</italic> and can therefore affect the risk of clinical malaria. We assessed here the effect of helminth infections on both the immunogenicity and efficacy of the GMZ2 malaria vaccine candidate, a recombinant protein consisting of conserved domains of GLURP and MSP3, two asexual blood-stage antigens of <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic>. Controlled human malaria infection (CHMI) was used to assess the efficacy of the vaccine.</p>
                </sec>
                <sec id="sec002">
                  <title>Methodology</title>
                  <p>In a randomized, double-blind Phase I clinical trial, fifty, healthy, lifelong malaria-exposed adult volunteers received three doses of GMZ2 adjuvanted with either Cationic Adjuvant Formulation (CAF) 01 or Alhydrogel, or a control vaccine (Rabies) on days (D) 0, D28 and D56, followed by direct venous inoculation (DVI) of 3,200 <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> sporozoites (PfSPZ Challenge) approximately 13 weeks after last vaccination to assess vaccine efficacy. Participants were followed-up on a daily basis with clinical examinations and thick blood smears to monitor <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> parasitemia for 35 days. Malaria was defined as the presence of <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> parasites in the blood associated with at least one symptom that can be associated to malaria over 35 days following DVI of PfSPZ Challenge. Soil-transmitted helminth (STH) infection was assessed by microscopy and by polymerase chain reaction (PCR) on stool, and <italic toggle="yes">Schistosoma</italic> infection was assessed by microscopy on urine. Participants were considered as infected if positive for any helminth either by PCR and/or microscopy at D0 and/or at D84 (Helm+) and were classified as mono-infection or co-infection. Total vaccine-specific IgG concentrations assessed on D84 were analysed as immunogenicity outcome.</p>
                </sec>
                <sec id="sec003">
                  <title>Main findings</title>
                  <p>The helminth in mono-infection, particularly <italic toggle="yes">Schistosoma haematobium</italic> and STH were significantly associated with earlier malaria episodes following CHMI, while no association was found in case of coinfection. In further analyses, the anti-GMZ2 IgG concentration on D84 was significantly higher in the <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic>-infected and significantly lower in the <italic toggle="yes">Strongyloides stercoralis-</italic>infected groups, compared to helminth-negative volunteers. Interesting, in the absence of helminth infection, a high anti-GMZ2 IgG concentration on D84 was significantly associated with protection against malaria.</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusions</title>
                  <p>Our results suggest that helminth infection may reduce naturally acquired and vaccine-induced protection against malaria. Vaccine-specific antibody concentrations on D84 may be associated with protection in participants with no helminth infection. These results suggest that helminth infection affect malaria vaccine immunogenicity and efficacy in helminth endemic countries.</p>
                </sec>
              </abstract>
              <abstract abstract-type="summary">
                <title>Author summary</title>
                <p>Helminths, mainly because of their immune regulatory effects, are able to impact the response induced by vaccines. In the context of clinical trial designs that measure accrual of natural infections during follow up or outcome of controlled human malaria infection (CHMI), their effect on vaccine efficacy can be measured. Indeed, most of such clinical trials on malaria vaccine candidates conducted in Africa, especially where the prevalence of helminths is high, have shown a certain limit in their efficacy and immunogenicity, as compared to results observed in European and U.S volunteers. The present analysis assessed the effect of helminths on GMZ2, a malaria vaccine candidate. We found a high level of anti-GMZ2 antibodies among volunteers not infected with helminths and protected against CHMI, indicating efficacy of the candidate vaccine in this population. We found a species-dependent effect of helminths on the level of post-immunization GMZ2-specific IgG concentration, and an association of helminths with an early onset of malaria in CHMI. Our findings reveal that helminths are associated with immunogenicity and may decrease the protective effect of antibodies induced by vaccination. Helminth infection status shall be determined when measuring the immunogenicity and efficacy of malaria vaccine candidates in helminth endemic countries.</p>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009139</institution-id>
                      <institution>Deutsches Zentrum für Infektionsforschung</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>TTU 03.801, TTU 03.702</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9101-2768</contrib-id>
                    <name>
                      <surname>Mordmüller</surname>
                      <given-names>Benjamin</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009139</institution-id>
                      <institution>Deutsches Zentrum für Infektionsforschung</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>TTU 03.703</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3197-5946</contrib-id>
                    <name>
                      <surname>Adegnika</surname>
                      <given-names>Ayôla Akim</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>5R44AI058375 and 5R44AI055229</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Hoffmann</surname>
                      <given-names>Stephen L.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>The GMZ2-CAF01 project received funding from Deutsches Zentrum für Infektionsforschung (Grant number: TTU 03.801 (BM), TTU 03.702 (BM), and TTU 03.703 (AAA)). Production of PfSPZ Challenge (NF54) by Sanaria was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (grant numbers 5R44AI058375 and 5R44AI055229 (SLH)). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="2"/>
                <page-count count="18"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>PLOS Publication Stage</meta-name>
                  <meta-value>vor-update-to-uncorrected-proof</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>Publication Update</meta-name>
                  <meta-value>2021-06-11</meta-value>
                </custom-meta>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript and its <xref rid="sec022" ref-type="sec">Supporting Information</xref> files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript and its <xref rid="sec022" ref-type="sec">Supporting Information</xref> files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>Helminth infections remain widespread and cause important neglected tropical diseases. The clinical presentations include anemia, malnutrition, developmental deficiencies causing significant morbidity and mortality [<xref rid="pntd.0009361.ref001" ref-type="bibr">1</xref>]. Blood flukes like <italic toggle="yes">Schistosoma haematobium</italic> and the group of soil-transmitted helminths (STH) including <italic toggle="yes">Ascaris lumbricoides</italic>, hookworm, <italic toggle="yes">Trichuris trichiura</italic> and <italic toggle="yes">Strongyloides stercoralis</italic> are most prevalent in developing countries, particularly in sub-Saharan Africa [<xref rid="pntd.0009361.ref002" ref-type="bibr">2</xref>], where malaria endemicity is high. In areas of co-endemicity, individuals frequently harbour these infections concomitantly. Several studies have already highlighted the role of helminth infections on the modulation of immune responses directed against <italic toggle="yes">Plasmodium falciparum</italic> antigens or against vaccine antigens, although with contradictory findings. Some studies reported a down-modulating effect of <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection on anti-<italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> immune responses such as negative association between the intensity of <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection and IgG1, IgG3 and IgG4 antibody subclass levels directed to malarial total schizont extract [<xref rid="pntd.0009361.ref003" ref-type="bibr">3</xref>]. <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection has also been shown to affect specific IgG1 directed to <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> (Pf) MSP1 and GLURP [<xref rid="pntd.0009361.ref004" ref-type="bibr">4</xref>], or to affect the anti-Pfs48/45 IgG level [<xref rid="pntd.0009361.ref005" ref-type="bibr">5</xref>]. By contrast, other studies have reported protection against malaria due to a Th2-enriched environment associated with <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection [<xref rid="pntd.0009361.ref006" ref-type="bibr">6</xref>], or anti-malarial protective antibody responses favored by <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium-P</italic>. <italic toggle="yes">falciparum</italic> coinfection [<xref rid="pntd.0009361.ref007" ref-type="bibr">7</xref>]. With regard to STH infection, some authors have reported an association with an increased risk of clinical malaria [<xref rid="pntd.0009361.ref008" ref-type="bibr">8</xref>] while other studies ruled out an effect of these helminth infections on the course of <italic toggle="yes">Plasmodium</italic> infection [<xref rid="pntd.0009361.ref009" ref-type="bibr">9</xref>,<xref rid="pntd.0009361.ref010" ref-type="bibr">10</xref>]. A recent study carried out on school-age children in rural area of Gabon showed an increased risk of <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> infection due to STH in schistosomiasis-positive children [<xref rid="pntd.0009361.ref011" ref-type="bibr">11</xref>]. Many studies have also been conducted to assess the effect of helminth infection on several commonly used vaccines [<xref rid="pntd.0009361.ref012" ref-type="bibr">12</xref>–<xref rid="pntd.0009361.ref018" ref-type="bibr">18</xref>], but little is known about their interaction with malaria vaccine candidates [<xref rid="pntd.0009361.ref019" ref-type="bibr">19</xref>–<xref rid="pntd.0009361.ref022" ref-type="bibr">22</xref>].</p>
              <p>GMZ2, a malaria vaccine candidate, is a recombinant fusion protein with fragments of <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> GLURP and MSP3 [<xref rid="pntd.0009361.ref023" ref-type="bibr">23</xref>] that showed good immunogenicity when formulated with aluminum hydroxide (alum) [<xref rid="pntd.0009361.ref024" ref-type="bibr">24</xref>–<xref rid="pntd.0009361.ref026" ref-type="bibr">26</xref>] or Cationic Adjuvant Formulation 01 (CAF01) adjuvant [<xref rid="pntd.0009361.ref027" ref-type="bibr">27</xref>]. Importantly, pre-school aged children vaccinated with GMZ2-alum and infected with <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic> had low vaccine-specific IgG responses compared to their non-infected counterparts or those infected with <italic toggle="yes">A</italic>. <italic toggle="yes">lumbricoides</italic> [<xref rid="pntd.0009361.ref020" ref-type="bibr">20</xref>]. That study clearly suggested that helminth infections affected GMZ2 vaccination-induced responses. We therefore hypothesized that helminth infection would negatively affect the immunogenicity and efficacy of GMZ2. Our study focused on <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> mainly. Indeed, the study area is endemic for <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> [<xref rid="pntd.0009361.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0009361.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0009361.ref028" ref-type="bibr">28</xref>,<xref rid="pntd.0009361.ref029" ref-type="bibr">29</xref>], although <italic toggle="yes">S</italic>. <italic toggle="yes">mansoni</italic> infections may also rarely occur [<xref rid="pntd.0009361.ref030" ref-type="bibr">30</xref>]. In the present exploratory analysis, our main objective was to assess the effect of <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> and STH on the time of the occurrence of malaria episodes after CHMI. In addition to that, we also assessed the effect of that helminth on the immunogenicity and the efficacy of GMZ2 when adjuvanted with either CAF01 or alum in Gabonese adults.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Methods</title>
              <sec id="sec007">
                <title>Ethics statement</title>
                <p>The original study was approved by the Comité National d’Ethique de la Recherche of Gabon, under the reference N°004/2015/SG/P. The trial was performed according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines and the Declaration of Helsinki. Written informed consent was obtained from all participants included in the study.</p>
              </sec>
              <sec id="sec008">
                <title>Study area</title>
                <p>The original study was conducted at the Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon (April 2015 –November 2015). Lambaréné is a semi-urban town, an area in which malaria [<xref rid="pntd.0009361.ref031" ref-type="bibr">31</xref>] and other parasitic infections particularly <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> and STH [<xref rid="pntd.0009361.ref028" ref-type="bibr">28</xref>] are endemic.</p>
              </sec>
              <sec id="sec009">
                <title>Study design</title>
                <p>The detailed design of the main study is described elsewhere [<xref rid="pntd.0009361.ref027" ref-type="bibr">27</xref>]. Briefly, eligible participants were randomized to receive three doses, 4-weeks apart (Day 0, Day 28, Day 56) of either 30μg or 100μg of GMZ2-CAF01, 100μg GMZ2-Alhydrogel (alum), or control rabies vaccine (Verorab, Sanofi Pasteur). Vaccine efficacy was assessed using standardized controlled human malaria infection (CHMI) by direct venous inoculation (DVI) of aseptic, purified, cryopreserved 3,200 <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> sporozoites (PfSPZ Challenge, Sanaria Inc.) approximately 13 weeks after the last immunization (on Day 56), and participants were followed-up on a daily basis with clinical and parasitological (thick blood smears for malaria) examinations for 35 days (<xref rid="pntd.0009361.s006" ref-type="supplementary-material">S1 Fig</xref>). Malaria was defined as the presence of <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> parasites associated with at least one malaria-attributable symptom over 35 days following DVI of PfSPZ Challenge. Typical malaria symptoms include fever, tachycardia, chills, rigor, sweats, headache, anorexia, nausea, vomiting, myalgia, arthralgia, chest pain, low back pain, abdominal pain and fatigue. CHMI results in 34 volunteers showed that five participants were fully protected (no parasitaemia and no malaria symptoms), fourteen controlled parasitaemia (low oscillating parasitemia and no symptoms) and fifteen had developed malaria (monotone increase of parasitemia with symptoms). The proportion of participants who developed malaria and the time to develop malaria were similar in all vaccinated groups [<xref rid="pntd.0009361.ref027" ref-type="bibr">27</xref>]. Participants were treated immediately when they met the malaria case definition. For participants without malaria, follow-up was censored at 35 days after PfSPZ Challenge inoculation (C+35) and treatment was administered irrespective of malaria status on that day. <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic> infection was treated with artemether-lumefantrine as the first line treatment. Urine samples were collected at D0 and at D84 on three consecutive days whereas stool samples were collected once at D0 and once at D84 (<xref rid="pntd.0009361.s006" ref-type="supplementary-material">S1 Fig</xref>). Urine and stool were examined for the presence of <italic toggle="yes">Schistosoma</italic> eggs and STH eggs or larvae, respectively. An aliquot of samples was frozen for DNA extraction and was processed after D84. Participants were considered as helminth infected if found positive on D0 and/or on D84 by any helminth species. All infected participants detected by microscopy were treated for helminth infection after D84 according to local guidelines.</p>
              </sec>
              <sec id="sec010">
                <title>Laboratory analysis</title>
                <sec id="sec011">
                  <title>GMZ2-specific IgG concentration measurements</title>
                  <p>Specific anti-GMZ2 IgG as well as those directed to MSP3 and GLURP were assessed in sera by Enzyme Linked ImmunoSorbent assay (ELISA), as described elsewhere [<xref rid="pntd.0009361.ref027" ref-type="bibr">27</xref>]. Briefly, the micro titration plates (Nunc) were coated with 100 μl of GMZ2, 100 μl of GLURP or 100 μl of MSP3 diluted in PBS, and plates were covered and incubated overnight at 4°C. Following plates washing, 150 μl of the blocking solution were added in each well and plates were incubated for 1 hour at room temperature. The plates were washed and the diluted serum samples were added in each well plate, followed by incubation for 2 hours at room temperature. After washing, the plates were incubated with 100 μl of peroxidase-conjugated goat anti-human IgG diluted to 1/65000 with the dilution solution, then incubated for 1 hour at room temperature. The plates were washed and 100 μl of the color solution (TMB One) were added, incubated for 20 min at temperature room in the dark, followed by addition of 100 μl of 0.2M sulfuric acid. The plates were immediately read at an absorbance of 450 nm and a reference at 620 nm using a microplate reader (Thermo Multiskan, Model 355).</p>
                </sec>
              </sec>
              <sec id="sec012">
                <title>Helminth detection by microscopy</title>
                <p>The Kato Katz enrichment and microscopy was used to detect eggs of hookworms, <italic toggle="yes">A</italic>. <italic toggle="yes">lumbricoides</italic>, and <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic> in stool samples, and coproculture was performed to detect larvae of hookworms and <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> as described elsewhere [<xref rid="pntd.0009361.ref028" ref-type="bibr">28</xref>,<xref rid="pntd.0009361.ref032" ref-type="bibr">32</xref>,<xref rid="pntd.0009361.ref033" ref-type="bibr">33</xref>]. Urine (around 10 mL) filtration followed by microscopy was used to detect the presence of <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> eggs in urine [<xref rid="pntd.0009361.ref029" ref-type="bibr">29</xref>]. Presence of microfilariae of <italic toggle="yes">Loa loa</italic> and <italic toggle="yes">Mansonella perstans</italic> in blood was assessed using the leuco-concentration technique [<xref rid="pntd.0009361.ref034" ref-type="bibr">34</xref>].</p>
              </sec>
              <sec id="sec013">
                <title>DNA extraction, amplification, and detection</title>
                <sec id="sec014">
                  <title>Parasite DNA from stool</title>
                  <p>DNA extraction, amplification, and detection Parasite DNA from stool was isolated and amplified following procedures previously described with minor modifications [<xref rid="pntd.0009361.ref035" ref-type="bibr">35</xref>–<xref rid="pntd.0009361.ref037" ref-type="bibr">37</xref>]. For the isolation of DNA, 100 mg of stool was suspended in 200 μL of phosphate-buffered saline (Sigma-Aldrich) with 2% polyvinylpolypyrolidone (Sigma-Aldrich) [<xref rid="pntd.0009361.ref036" ref-type="bibr">36</xref>], followed by homogenization and bead-beating performed in a 2 ml tube containing Lysing Matrix E (MP Biomedicals). Suspended feces were frozen at -70°C for 30 min. After thawing, suspensions were treated with sodium dodecyl sulphate-proteinase K for 2 h at 55°C [<xref rid="pntd.0009361.ref037" ref-type="bibr">37</xref>] and DNA was extracted with the QIAamp DNA mini kit (QIAgen) according to the manufacturer’s instruction. During the isolation an internal extraction control, 10<sup>3</sup> PFU/ml phocine herpes virus 1 (PhHV-1) was added within the isolation lysis buffer in each sample [<xref rid="pntd.0009361.ref037" ref-type="bibr">37</xref>]. Previously described PCR primer and probe sequences [<xref rid="pntd.0009361.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0009361.ref039" ref-type="bibr">39</xref>] were used for the amplification of <italic toggle="yes">A</italic>. <italic toggle="yes">lumbricoides</italic>, <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic>, <italic toggle="yes">Necator americanus</italic> and <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic>. Those species were the most detected by microscopy in our study and are known to be most prevalent in the study area [<xref rid="pntd.0009361.ref040" ref-type="bibr">40</xref>]. Primer and probe concentrations were optimized for the assay (<xref rid="pntd.0009361.s001" ref-type="supplementary-material">S1</xref> and <xref rid="pntd.0009361.s002" ref-type="supplementary-material">S2</xref> Tables). Amplification conditions were 15 min at 95°C followed by 45 cycles of 15 s at 95°C, 30 s at 60°C and 30 s at 72°C respectively. Amplification and detection of fluorescence was done on a LightCycler 480 (Roche) machine. Cq values ≤ 39 were considered as positive. No DNA extraction was done on urine samples.</p>
                </sec>
              </sec>
              <sec id="sec015">
                <title>Statistical analyses</title>
                <p>Data were exported in R version 3.4.2 for statistical analysis. Graphs were made using GraphPad Prism Version 6 and R. Study participants were divided in two main groups; those found to be uninfected with helminths by both qPCR and microscopy formed the helminth negative (Helm-) group, and those shown to be infected with helminths either by qPCR and/or by microscopy formed the helminth positive (Helm+) group. In order to assess the effect of individual helminth species, subgroups were formed based on the respective mono-infections i.e. <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> (Sh+) and <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> (Str+). Due to the very low number of cases, and as no considerable difference in concentration of anti-GMZ2 antibodies was found between these both STH, <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic> and hookworm infections were merged into the third Tt+/Hw+ sub-study group. The remaining study participants constituted the coinfection (CoInf+) sub-study group as they were infected with more than one parasite. The Mann-Whitney non-parametric test was used to compare characteristics and the haematological profiles of the study population, while linear regression was used for univariable and multivariable analyses to compare specific IgG levels between study groups, using baseline vaccine-specific total IgG concentration as variable of adjustment. The unpaired t test was performed to compare the specific IgG concentration between each combination of two groups after stratification of the helminth infected group, following by ANOVA test with Holm-Sidak’s multiple comparisons. A Kaplan-Meier curve and Log-rank tests were used to assess the time to malaria episodes between study groups and subgroups. All analyses were considered exploratory. The tests were considered statistically significant for a <italic toggle="yes">p-value</italic> less than 0.05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec016">
              <title>Results</title>
              <sec id="sec017">
                <title>Participants flow and characteristics of the study population</title>
                <p>Of the forty-five (45) participants from the fifty (50) included in the clinical trial and for whom all data are available, five (5) were excluded from analysis as they received the control vaccine (Verorab) and one further patient was excluded due to missing data for the PCR on stool samples for STH detection. Data on thirty-nine participants are therefore considered for analysis (<xref rid="pntd.0009361.g001" ref-type="fig">Fig 1</xref>). Of them, thirteen (13) were infected with at least one STH species (Hookworm, <italic toggle="yes">A</italic>. <italic toggle="yes">lumbricoides</italic>, <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic>, <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic>) as determined by the presence of eggs or larvae in stool using microscopy, while twenty-six (26) were considered uninfected. Using the PCR method, a total of nineteen (19) participants were found to be infected with at least one species of STH, including 6 of those for whom microscopy was negative, while the twenty (20) other participants were uninfected (<xref rid="pntd.0009361.g001" ref-type="fig">Fig 1</xref>).</p>
                <fig position="float" id="pntd.0009361.g001">
                  <object-id pub-id-type="doi">10.1371/journal.pntd.0009361.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Flow chart of the study participants.</title>
                    <p>PCR: Polymerase chain reaction STH: Soil-transmitted helminth SH: <italic toggle="yes">Schistosoma haematobium</italic> N = number</p>
                  </caption>
                  <graphic xlink:href="pntd.0009361.g001" position="float"/>
                </fig>
                <p>Assessing participants’ schistosomiasis status using urine filtration, a total of fourteen (14) participants had <italic toggle="yes">Schistosoma</italic> eggs in urine, including ten (10) participants also infected with STH using microscopy and/or PCR, and twenty-five (25) participants had no <italic toggle="yes">Schistosoma</italic> eggs, including nine (9) participants infected with STH using microscopy and/or PCR. No <italic toggle="yes">Schistosoma</italic> eggs were found in stool samples, and no filarial infection was detected in the study population. In summary, 16 (41%) participants were classified as uninfected (Helm-), and 23 (59%) were classified as infected (Helm+) (<xref rid="pntd.0009361.g001" ref-type="fig">Fig 1</xref>).</p>
                <p>Among the participants included in the Helm+ group, 4 had <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> alone, 4 had <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic>, 2 had <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic> and 1 had hookworm. As detailed in <xref rid="pntd.0009361.s003" ref-type="supplementary-material">S3 Table</xref>, 12 participants were infected with more than one helminth species and were included in a CoInf group, with <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> being the most prevalent species (34%), followed by <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic> (28%), Hookworm (21%), <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> (10%) and <italic toggle="yes">A</italic>. <italic toggle="yes">lumbricoides</italic> (7%), respectively. All 39 participants included in this analysis were men with a median age (interquartile range) of 23 (5.5) years. Compared to the Helm- group, the hemoglobin level was lower in the Helm+ group (<italic toggle="yes">p-value</italic> = 0.02) while the levels of white blood cells (<italic toggle="yes">p-value</italic> = 0.0008), lymphocytes (<italic toggle="yes">p-value</italic> = 0.001), eosinophils (<italic toggle="yes">p-value</italic> = 0.0006) and basophils (<italic toggle="yes">p-value</italic> = 0.001) were increased (<xref rid="pntd.0009361.t001" ref-type="table">Table 1</xref>).</p>
                <table-wrap position="float" id="pntd.0009361.t001">
                  <object-id pub-id-type="doi">10.1371/journal.pntd.0009361.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Characteristics and hematological profile of the study population on D84 with regard to helminth status.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pntd.0009361.t001" id="pntd.0009361.t001g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">Helminth negative</th>
                          <th align="center" rowspan="1" colspan="1">Helminth positive</th>
                          <th align="center" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-value<xref rid="t001fn002" ref-type="table-fn">*</xref></th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                            <bold>N (%)</bold>
                          </td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">16 (41)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">23 (59)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">-</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Age (years)</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">25 (10)</td>
                          <td align="center" rowspan="1" colspan="1">22 (4)</td>
                          <td align="center" rowspan="1" colspan="1">0.06</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                            <bold>BMI (kg/m</bold>
                            <sup>
                              <bold>2</bold>
                            </sup>
                            <bold>)</bold>
                          </td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">22.40 (3.05)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">22.50 (2.5)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">0.79</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Hb (g/dL)</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">14.7 (1.4)</td>
                          <td align="center" rowspan="1" colspan="1">13.6 (1.6)</td>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>0.02</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                            <bold>WBC (x10</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>/mm</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>)</bold>
                          </td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">4.25 (1.37)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">5.70 (1.55)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                            <bold>0.0008</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Lymphocytes (x10</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>/mm</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>)</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">2.01 (0.49)</td>
                          <td align="center" rowspan="1" colspan="1">2.42 (0.68)</td>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>0.001</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                            <bold>Neutrophils (x10</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>/mm</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>)</bold>
                          </td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">1.97 (1.18)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">2.62 (1.76)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">0.05</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Eosinophils (x10</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>/mm</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>)</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">0.07 (1.18)</td>
                          <td align="center" rowspan="1" colspan="1">0.33 (0.82)</td>
                          <td align="center" rowspan="1" colspan="1">
                            <bold>0.0006</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                            <bold>Basophils (x10</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>/mm</bold>
                            <sup>
                              <bold>3</bold>
                            </sup>
                            <bold>)</bold>
                          </td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">0.04 (0.03)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">0.06 (0.04)</td>
                          <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                            <bold>0.001</bold>
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p>BMI = Body mass index, Hb = Hemoglobin, WBC = White blood cells.</p>
                    </fn>
                    <fn id="t001fn002">
                      <p>* Mann-Whitney test. Data are median (interquartile range)</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec018">
                <title>Helminth infection and vaccine-specific IgG concentration</title>
                <p>As shown elsewhere [<xref rid="pntd.0009361.ref027" ref-type="bibr">27</xref>] and confirmed here, immunization with GMZ2 induced a high levels of anti-GMZ2, anti-MSP3 and anti-GLURP IgG antibodies. The differences in antibody levels between D0 and D84 are presented in <xref rid="pntd.0009361.s007" ref-type="supplementary-material">S2 Fig</xref>. Here, we compared the antibody concentration on D84 between Helm- and Helm+ groups, as well as with infected subgroups. No statistically significant relationship was observed between helminth status and level of anti-GMZ2 IgG (<italic toggle="yes">p-value</italic> = 0.49), anti-MSP3 (<italic toggle="yes">p-value</italic> = 0.18) and anti-GLURP IgG (<italic toggle="yes">p-value</italic> = 0.30) concentration (<xref rid="pntd.0009361.g002" ref-type="fig">Fig 2A–2C</xref>). No significant relationship was observed when applying multivariate analyses.</p>
                <fig position="float" id="pntd.0009361.g002">
                  <object-id pub-id-type="doi">10.1371/journal.pntd.0009361.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Post immunization antibody concentration at D84 in helminth uninfected and infected groups (Helm- and Helm+).</title>
                    <p>Fig 2 illustrates the log of GMZ2-specific (A), MSP3-specific (B), GLURP-specific (C) IgG concentration at D84 in helminth negative (Helm-, n = 16) and helminth positive (Helm+, n = 23) groups. Comparisons were performed by univariate and multivariate linear regression adjusted for baseline data as independent covariable. The graphs are mean ± standard deviation. Statistical significance was set for p value below 0.05. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. NS = Non-significant.</p>
                  </caption>
                  <graphic xlink:href="pntd.0009361.g002" position="float"/>
                </fig>
                <p>As presented in <xref rid="pntd.0009361.t002" ref-type="table">Table 2</xref>, we found at univariate analysis no relationship between helminths status and the level of the three antibody concentrations measured and this in the three vaccine groups.</p>
                <table-wrap position="float" id="pntd.0009361.t002">
                  <object-id pub-id-type="doi">10.1371/journal.pntd.0009361.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Comparison of antibody log concentrations mean (±SD) between helminth infection groups at D84 stratified by study vaccination groups.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pntd.0009361.t002" id="pntd.0009361.t002g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="2" colspan="1"/>
                          <th align="center" colspan="3" rowspan="1">100μg GMZ2-Alum</th>
                          <th align="center" colspan="3" rowspan="1">30μg GMZ2-CAF01</th>
                          <th align="center" colspan="3" rowspan="1">100μg GMZ2-CAF01</th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Helm- (n = 07)</th>
                          <th align="center" rowspan="1" colspan="1">Helm+ (n = 04)</th>
                          <th align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">p-value</italic>
                          </th>
                          <th align="center" rowspan="1" colspan="1">Helm- (n = 03)</th>
                          <th align="center" rowspan="1" colspan="1">Helm+ (n = 05)</th>
                          <th align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">p-value</italic>
                          </th>
                          <th align="center" rowspan="1" colspan="1">Helm- (n = 06)</th>
                          <th align="center" rowspan="1" colspan="1">Helm+ (n = 14)</th>
                          <th align="center" rowspan="1" colspan="1">
                            <italic toggle="yes">p-value</italic>
                          </th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Anti-GMZ2 IgG</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">3.47 (<bold>±</bold>0.15)</td>
                          <td align="center" rowspan="1" colspan="1">3.64 (<bold>±</bold>0.11)</td>
                          <td align="center" rowspan="1" colspan="1">0.09</td>
                          <td align="center" rowspan="1" colspan="1">3.51 (<bold>±</bold>0.14)</td>
                          <td align="center" rowspan="1" colspan="1">3.53 (<bold>±</bold>0.22)</td>
                          <td align="center" rowspan="1" colspan="1">0.90</td>
                          <td align="center" rowspan="1" colspan="1">3.50 (<bold>±</bold>0.13)</td>
                          <td align="center" rowspan="1" colspan="1">3.47 (<bold>±</bold>0.20)</td>
                          <td align="center" rowspan="1" colspan="1">0.70</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Anti-MSP3 IgG</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">3.52 (<bold>±</bold>0.45)</td>
                          <td align="center" rowspan="1" colspan="1">3.34 (<bold>±</bold>0.36)</td>
                          <td align="center" rowspan="1" colspan="1">0.52</td>
                          <td align="center" rowspan="1" colspan="1">3.60 (<bold>±</bold>0.65)</td>
                          <td align="center" rowspan="1" colspan="1">3.19 (<bold>±</bold>0.25)</td>
                          <td align="center" rowspan="1" colspan="1">0.23</td>
                          <td align="center" rowspan="1" colspan="1">3.32 (<bold>±</bold>0.38)</td>
                          <td align="center" rowspan="1" colspan="1">3.51 (<bold>±</bold>0.38)</td>
                          <td align="center" rowspan="1" colspan="1">0.30</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Anti-GLURP IgG</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">3.52 (<bold>±</bold>0.16)</td>
                          <td align="center" rowspan="1" colspan="1">353 (<bold>±</bold>0.11)</td>
                          <td align="center" rowspan="1" colspan="1">0.91</td>
                          <td align="center" rowspan="1" colspan="1">3.39 (<bold>±</bold>0.27)</td>
                          <td align="center" rowspan="1" colspan="1">3.46 (<bold>±</bold>0.29)</td>
                          <td align="center" rowspan="1" colspan="1">0.73</td>
                          <td align="center" rowspan="1" colspan="1">3.64 (<bold>±</bold>0.16)</td>
                          <td align="center" rowspan="1" colspan="1">3.66 (<bold>±</bold>0.25)</td>
                          <td align="center" rowspan="1" colspan="1">0.88</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p>Helm+ = positive for helminth infection</p>
                    </fn>
                    <fn id="t002fn002">
                      <p>Helm- = negative for helminth infection</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Considering the sub-study groups, we found a relationship between <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> status (<italic toggle="yes">p-value</italic> = 0.01), <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> (<italic toggle="yes">p-value</italic> = 0.03) status and vaccine-specific IgG concentration on D84. Compared to anti-GMZ2 IgG concentration on D84 in those uninfected (mean log concentration ±SD: 3.49 ±0.14), participants infected with <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> alone presented a higher level of anti-GMZ2 IgG (3.69 ±0.10), while those infected with <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> alone had lower anti-GMZ2 IgG levels (3.32 ±0.19) (<xref rid="pntd.0009361.g003" ref-type="fig">Fig 3A</xref>). Additionally, a significantly lower level of anti-GMZ2 IgG was observed in Str+ individuals compared with the Sh+ individuals (<italic toggle="yes">p-value</italic> = 0.0008), Tt+/Hw+ individuals (3.62 ±0.16, <italic toggle="yes">p-value</italic> = 0.003) and CoInf+ individuals (3.49 ±0.17, <italic toggle="yes">p-value</italic> = 0.03) (<xref rid="pntd.0009361.g003" ref-type="fig">Fig 3A</xref>). No significant differences between the groups were observed when applying a correction for multiple comparison. In addition, no relationships were observed for either anti-MSP3 or anti-GLURP IgG levels and helminth status (<xref rid="pntd.0009361.g003" ref-type="fig">Fig 3B and 3C</xref>).</p>
                <fig position="float" id="pntd.0009361.g003">
                  <object-id pub-id-type="doi">10.1371/journal.pntd.0009361.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Post immunization antibody concentration at D84 in Helm- and Helm+ subgroups.</title>
                    <p>Fig 3 illustrates the log of specific-GMZ2 (A), specific-MSP3 (B), specific GLURP (C) IgG concentration at D84 in Helm- and mono-infected by <italic toggle="yes">Schistosoma haematobium</italic> (Sh+, n = 4), those mono-infected with Strongyloides (Str+, n = 4), those mono-infected with <italic toggle="yes">Trichuris trichiura</italic> or hookworm (Tt+/Hw+, n = 3), and those coinfected by at least two different helminths (Coinf+, n = 12). The comparison was performed by multivariate linear regression adjusted for baseline vaccine-specific total IgG concentration as independent covariable. The graphs show mean ± standard deviation. Statistical significance was set for p value below 0.05 and is indicated when statistically significant. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. NS = Non-significant.</p>
                  </caption>
                  <graphic xlink:href="pntd.0009361.g003" position="float"/>
                </fig>
              </sec>
              <sec id="sec019">
                <title>Helminth status and protection from malaria</title>
                <p>Assessing the time to the occurrence of malaria episodes after CHMI between helminth groups, we found a relationship between any helminth infection and time to develop malaria (Log-Rank test: <italic toggle="yes">p-value</italic> = 0.039), as depicted in <xref rid="pntd.0009361.g004" ref-type="fig">Fig 4A</xref>, such that those with helminth infection developed malaria significantly earlier than those without. When considering the infected subgroups, <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> (Log-Rank test: <italic toggle="yes">p-value</italic> = 0.008) and STH (Log-Rank test: <italic toggle="yes">p-value</italic> = 0.037) infections were associated with faster times to malaria (<xref rid="pntd.0009361.g004" ref-type="fig">Fig 4B and 4C</xref>). No statistically significant difference was observed between coinfection status and time to develop malaria (Log-Rank test: <italic toggle="yes">p-value</italic> = 0.19, <xref rid="pntd.0009361.g004" ref-type="fig">Fig 4D</xref>).</p>
                <fig position="float" id="pntd.0009361.g004">
                  <object-id pub-id-type="doi">10.1371/journal.pntd.0009361.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Time to occurrence of malaria episodes after CHMI.</title>
                  </caption>
                  <graphic xlink:href="pntd.0009361.g004" position="float"/>
                </fig>
                <p>The proportion of participants who did not develop malaria after CHMI is presented for Helm- (8/11, 72.7%) and Helm+ (7/16, 43.8%) groups (A), for Helm- and Sh+ (1/3, 33.3%) (B), for Helm- and Sth+ (1/3, 33.3%) (C), and in Helm- and CoInf+ (5/10, 50%) (D).</p>
                <p>In additional analyses in the helminth coinfected group assessing the distribution of helminths species between malaria outcome groups following CHMI, the results showed that the distribution of helminth species was different between participants who did and those who did not develop malaria (<xref rid="pntd.0009361.s004" ref-type="supplementary-material">S4 Table</xref>).</p>
              </sec>
              <sec id="sec020">
                <title>Vaccine-specific IgG level and CHMI outcome according to helminth status</title>
                <p>As mentioned elsewhere [<xref rid="pntd.0009361.ref027" ref-type="bibr">27</xref>], and confirmed here (<xref rid="pntd.0009361.g005" ref-type="fig">Fig 5A</xref>), no difference was found between vaccine-specific IgG concentration on D84 and protection against clinical malaria following CHMI. We therefore assessed whether this observation differed according to helminth infection status. In a stratified analysis, a relationship was found between the occurrence of clinical malaria after CHMI and the anti-GMZ2 IgG concentration (<italic toggle="yes">p-value</italic> = 0.048) on D84 in the Helm- group. The anti-GMZ2 IgG concentration was higher among those who did not experience malaria (3.51 ±0.13) compared to those who experienced malaria (3.32 ±0.0.6, <xref rid="pntd.0009361.g005" ref-type="fig">Fig 5B</xref>), although the increase was not statistically significant when adjusted with baseline anti-GMZ2 IgG concentration. In the Helm+ group, no such relationship was found (<italic toggle="yes">p-value</italic> = 0.51, <xref rid="pntd.0009361.g005" ref-type="fig">Fig 5C</xref>).</p>
                <fig position="float" id="pntd.0009361.g005">
                  <object-id pub-id-type="doi">10.1371/journal.pntd.0009361.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Anti-GMZ2 IgG concentration and CHMI outcome groups according to helminth status Comparison of vaccine-specific total IgG concentration at D84 between those having clinical malaria (monotone increase of parasitemia with symptoms) and those without clinical malaria (low oscillating parasitemia and no symptoms (control) and those with no parasitemia and no symptoms (protected)) after the CHMI was performed in all participants (n = 12 <italic toggle="yes">vs</italic> 14, 5A), in helminth uninfected (n = 3 <italic toggle="yes">vs</italic> 8, 5B), and infected (n = 9 <italic toggle="yes">vs</italic> 7, 5C) participants.</title>
                    <p>The comparison was done by multivariate linear regression using baseline vaccine-specific total IgG concentration as variable of adjustment. Statistical significance was set for p value below 0.05. *p&lt;0.05 NS = Non-significant.</p>
                  </caption>
                  <graphic xlink:href="pntd.0009361.g005" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec021">
              <title>Discussion</title>
              <p>The results of the study presented here show that helminth species can differentially affect the specific immune response following administration of a malaria vaccine candidate: participants infected with <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> had higher GMZ2-specific IgG on D84 post-first immunization, while <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> infection was associated with a lower IgG response on D84 compared to that of helminth uninfected participants.</p>
              <p>From our analysis, in comparison to helminth uninfected individuals, <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection was associated with a higher post-immunization anti-GMZ2 IgG response. It has been shown that <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection is associated with an increased systemic concentration of the C3d molecule of the complement system [<xref rid="pntd.0009361.ref041" ref-type="bibr">41</xref>], which can enhance B cell signaling [<xref rid="pntd.0009361.ref042" ref-type="bibr">42</xref>]. We speculate that this or a similar adjuvant-like phenomenon may explain our findings. Moreover, <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> could augment antibody production by influencing the biological environment through enhanced IL-4 production [<xref rid="pntd.0009361.ref006" ref-type="bibr">6</xref>], favoring antimalarial antibody production [<xref rid="pntd.0009361.ref043" ref-type="bibr">43</xref>]. It should be noted that <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection had no significant effect on the antibody responses directed to either MSP3 or GLURP, the two antigens combined in GMZ2, in contrast to the findings of a recent study [<xref rid="pntd.0009361.ref044" ref-type="bibr">44</xref>], although the level of anti-GLURP IgG concentration was indeed higher in <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infected compared to uninfected individuals, but this difference was not statistically significant. It is well known that MSP3 constitutes a less immunogenic component of GMZ2 [<xref rid="pntd.0009361.ref024" ref-type="bibr">24</xref>,<xref rid="pntd.0009361.ref025" ref-type="bibr">25</xref>], possibly explaining this observation. The intensity of <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> infection may have a determining role in its effect on other parasites. In our study cohort, the <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> egg count in infected participants was low (<xref rid="pntd.0009361.s005" ref-type="supplementary-material">S5 Table</xref>), possibly explaining the absence of any deleterious effect on the immunogenicity of GMZ2.</p>
              <p>In contrast to our observations in <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium-</italic>infected individuals, we observed low post-immunization anti-GMZ2 IgG levels in <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic>-infected participants compared to post-immunization anti-GMZ2 IgG concentration in the helminth uninfected group. <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> has been shown to reduce B cell numbers, and to affect B cell responses during latent tuberculosis infection [<xref rid="pntd.0009361.ref045" ref-type="bibr">45</xref>]. <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> can also reduce the induction of mycobacterial-specific IgM and IgG responses and the expression levels of the B-cell growth factors APRIL and BAFF [<xref rid="pntd.0009361.ref045" ref-type="bibr">45</xref>]. There is virtually no data on the effect of this parasite on the immunogenicity of malaria vaccine antigens. In the present study, we show that this STH can negatively affect the vaccine IgG concentration as we have shown in a recent study conducted in children. We hypothesize that the presence of <italic toggle="yes">S</italic>. <italic toggle="yes">stercoralis</italic> in our study population could considerably inhibit B cell activity, via, for example, the induction of specific regulatory mechanisms including Treg [<xref rid="pntd.0009361.ref046" ref-type="bibr">46</xref>].</p>
              <p>In our study, co-infected participants had a similar specific IgG concentration compared to those uninfected, indicating potentially opposing effects of different species, possibly explaining the lower concentration of anti-GMZ2 IgG in the co-infected group compared to those harbouring <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> alone; the question thus arises as to the importance of considering the effect of every single species of helminths separately on GMZ2 immunogenicity. Indeed, Esen and colleagues showed that infection with <italic toggle="yes">T</italic>. <italic toggle="yes">trichiura</italic> affects the concentration of anti-GMZ2 IgG in children, whilst infection with <italic toggle="yes">A</italic>. <italic toggle="yes">lumbricoides</italic> had no such effect [<xref rid="pntd.0009361.ref020" ref-type="bibr">20</xref>], strongly suggesting a species-dependent effect.</p>
              <p>Investigating the delay to development of malaria episodes with regard to helminth status, we observed that volunteers infected with helminths, irrespective of the species, develop malaria episodes earlier than those without these infections, possibly essentially due to <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> and STH. Such an effect of <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> and STH has been observed in the same area in young children [<xref rid="pntd.0009361.ref011" ref-type="bibr">11</xref>], suggesting that helminths could affect malaria vaccine efficacy in adults through various mechanisms neither well known nor well described. We hypothesize that this effect is helminth species dependent. However, given the relatively small number of helminth mono-infected volunteers and the comparatively higher number of coinfected volunteers we had, it is difficult to elucidate any one infection’s role on susceptibility to malaria. Indeed, the absence of such an effect in co-infected volunteers supports the idea of opposing effects of these different helminth species, although the differences observed in the proportions of different helminths species between those who did and did not developed malaria after CHMI in the helminth coinfected could also explain the fact.</p>
              <p>We found that those with no helminth infection who had a higher vaccine-specific IgG response on D84 were protected against clinical malaria. Antibodies are known to play an important role in acquired protective immunity against blood-stage malaria either through inhibition of merozoite invasion of red blood cells or antibody-mediated cell cytotoxicity against infected red blood cells [<xref rid="pntd.0009361.ref047" ref-type="bibr">47</xref>,<xref rid="pntd.0009361.ref048" ref-type="bibr">48</xref>]. From this standpoint, we hypothesize that the presence of helminths could affect the quality of the antibodies produced in response to the vaccine candidate, as described elsewhere [<xref rid="pntd.0009361.ref049" ref-type="bibr">49</xref>,<xref rid="pntd.0009361.ref050" ref-type="bibr">50</xref>], influencing their effect on <italic toggle="yes">P</italic>. <italic toggle="yes">falciparum</italic>. We speculate that the lack of GMZ2 efficacy shown in our study may therefore at least be partly due to the presence of helminths.</p>
              <p>We recognize limitations to this study, notably the small number of infected individuals in the subgroups, precluding further in-depth statistical tests. In addition, the study was conducted exclusively on males, precluding the extrapolation of any conclusions to the population at large. The observational and exploratory nature of the study also means that causality cannot be easily addressed. Furthermore, the helminth groups are not randomized and likely differ systematically in other variables that may introduce bias. Another possible limitation is the CHMI, since it has never been used before in this context. Additionally, the fact that not all the available plasma at different time points were analyzed, and that the helminth diagnosis was not made between D0 and D84, weakens the results, because it would allow to check if these same observations are made at other time points. Despite these limitations, we did find some relevant and significant results and we believe that our findings provide important information on the negative effect of helminth infection on vaccine-induced protective immunity, and a probable double impact that helminths and <italic toggle="yes">S</italic>. <italic toggle="yes">haematobium</italic> in particular, could have on other parasites [<xref rid="pntd.0009361.ref011" ref-type="bibr">11</xref>] or on the response to vaccine antigens. Other studies on the effect of helminths in malaria vaccine candidates on larger cohorts are needed to further corroborate these findings.</p>
              <p>In summary, we report that the effect of helminth infection status on anti-GMZ2 immunogenicity could be parasite species-dependent, and that vaccine efficacy can be altered by helminth infections. If confirmed in other large cohort studies, it would clearly be therefore highly relevant to take into account volunteers’ helminth status when assessing the immunogenicity and efficacy of malaria vaccine candidates. A conclusion of this understanding may be to only include participants free of helminths, particularly in the early stages of clinical development of vaccines in which small sample sizes are a requisite.</p>
            </sec>
            <sec id="sec022" sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="pntd.0009361.s001" position="float" content-type="local-data">
                <label>S1 Table</label>
                <caption>
                  <title>Oligonucleotides List for the real time amplification.</title>
                  <p>BHQ: Black hole quencher All the primers and probes were ordered by Eurofines. For the amplification we always did a triplex.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pntd.0009361.s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pntd.0009361.s002" position="float" content-type="local-data">
                <label>S2 Table</label>
                <caption>
                  <title>PCR mix optimized for our Study.</title>
                  <p>Different primers and probes concentrations were tested to evaluate the best one for our assay. We used the following primers and probes concentration for each species: 0.1 μM, 0.2 μM, 0.3 μM and 0.4 μM. After checking and analyzing the PCR amplification curves, we decided to use the 0.2 μM concentration. <xref rid="pntd.0009361.t002" ref-type="table">Table 2</xref> shows the chosen setting for our assay. # Volume depending of the reagent start concentration.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pntd.0009361.s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pntd.0009361.s003" position="float" content-type="local-data">
                <label>S3 Table</label>
                <caption>
                  <title>Proportion of helminth species in coinfected groups at D0 and/or at D84.</title>
                  <p>Infection (+) either by PCR and/or microscopy at D0 and/or at D84 No infection (-) either by PCR and/or microscopy at D0 and/or at D84.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pntd.0009361.s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pntd.0009361.s004" position="float" content-type="local-data">
                <label>S4 Table</label>
                <caption>
                  <title>Distribution of helminth species in the helminth co-infected group in individuals who did or did not develop malaria following CHMI.</title>
                  <p>The percentage of each helminth specie in the helminth coinfected group in those who did and did not develop malaria was calculated following the formula: (Number of volunteers infected at D0 and/or D84 x 100) / Total number of volunteers who did (Malaria) or did not develop malaria (No malaria) following CHMI.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pntd.0009361.s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pntd.0009361.s005" position="float" content-type="local-data">
                <label>S5 Table</label>
                <caption>
                  <title><italic toggle="yes">Schistosoma haematobium</italic> egg counts per subject in infected volunteers.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pntd.0009361.s005.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pntd.0009361.s006" position="float" content-type="local-data">
                <label>S1 Fig</label>
                <caption>
                  <title>Timeline of immunizations and blood sample collection I, II and III represent respectively the first, second and the third immunization.</title>
                  <p>Blood collection was done before each immunization and at seven, fourteen days after the first and second immunization, and seven, fourteen and twenty-eight days after the third immunization, as well as one day before the CHMI and thirty-five day after the CHMI. The asterisk represents the time of urine and stool collection.</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pntd.0009361.s006.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pntd.0009361.s007" position="float" content-type="local-data">
                <label>S2 Fig</label>
                <caption>
                  <p>Anti-GMZ2, anti-MSP3 and anti-GLURP IgG concentrations between D0 and D84 in vaccination groups Figures show the log of GMZ2-specific (A), MSP3-specific (B), GLURP-specific (C) IgG concentrations at D0 (filled dot) and at D84 (unfilled dot) in participants vaccinated with Rabies vaccine, 100 μg GMZ2-Alhydrogel, 30 μg GMZ2-CAF01; and 100 μg GMZ2-CAF01. The comparison was performed using a paired t-test. The graphs show mean ± standard deviation. Statistical significance was set for p value below 0.05 *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. NS = Non-significant.</p>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pntd.0009361.s007.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pntd.0009361.s008" position="float" content-type="local-data">
                <label>S1 Data</label>
                <caption>
                  <title>Data underlying the findings.</title>
                  <p>(XLSX)</p>
                </caption>
                <media xlink:href="pntd.0009361.s008.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We are grateful to the study participants, nurses, and field-workers involved in this clinical study, in particular providers of CAF01 and PfSPZ Challenge, and all immunology/parasitology team of CERMEL and Institute of Tropical Medicine of Tübingen.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pntd.0009361.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Pullan</surname><given-names>RL</given-names></name>, <name><surname>Smith</surname><given-names>JL</given-names></name>, <name><surname>Jasrasaria</surname><given-names>R</given-names></name>, <name><surname>Brooker</surname><given-names>SJ</given-names></name>. <article-title>Global numbers of infection and disease burden of soil transmitted helminth infections in 2010.</article-title><source>Parasit Vectors.</source><year>2014</year><month>Jan</month><day>21</day>;<volume>7</volume>:<fpage>37</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1756-3305-7-37</pub-id><?supplied-pmid 24447578?><pub-id pub-id-type="pmid">24447578</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Hotez</surname><given-names>PJ</given-names></name>, <name><surname>Kamath</surname><given-names>A</given-names></name>. <article-title>Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden.</article-title><source>PLoS Negl Trop Dis.</source><year>2009</year><month>Aug</month><day>25</day>;<volume>3</volume>(<issue>8</issue>):<fpage>e412</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0000412</pub-id><?supplied-pmid 19707588?><pub-id pub-id-type="pmid">19707588</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Mutapi</surname><given-names>F</given-names></name>, <name><surname>Roussilhon</surname><given-names>C</given-names></name>, <name><surname>Mduluza</surname><given-names>T</given-names></name>, <name><surname>Druilhe</surname><given-names>P</given-names></name>. <article-title>Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium</article-title>. <source>Mem Inst Oswaldo Cruz</source>. <year>2007</year><month>Jun</month>;<volume>102</volume>(<issue>3</issue>):<fpage>405</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1590/s0074-02762007005000046</pub-id>
<?supplied-pmid 17568947?><pub-id pub-id-type="pmid">17568947</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Courtin</surname><given-names>D</given-names></name>, <name><surname>Djilali-Saiah</surname><given-names>A</given-names></name>, <name><surname>Milet</surname><given-names>J</given-names></name>, <name><surname>Soulard</surname><given-names>V</given-names></name>, <name><surname>Gaye</surname><given-names>O</given-names></name>, <name><surname>Migot-Nabias</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Schistosoma haematobium infection affects Plasmodium falciparum-specific IgG responses associated with protection against malaria</article-title>. <source>Parasite Immunol</source>. <year>2011</year><month>Feb</month>;<volume>33</volume>(<issue>2</issue>):<fpage>124</fpage>–<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-3024.2010.01267.x</pub-id>
<?supplied-pmid 21226725?><pub-id pub-id-type="pmid">21226725</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Ateba-Ngoa</surname><given-names>U</given-names></name>, <name><surname>Jones</surname><given-names>S</given-names></name>, <name><surname>Zinsou</surname><given-names>JF</given-names></name>, <name><surname>Honkpehedji</surname><given-names>J</given-names></name>, <name><surname>Adegnika</surname><given-names>AA</given-names></name>, <name><surname>Agobe</surname><given-names>JC</given-names></name>, <etal>et al</etal>. <article-title>Associations Between Helminth Infections, Plasmodium falciparum Parasite Carriage and Antibody Responses to Sexual and Asexual Stage Malarial Antigens</article-title>. <source>Am J Trop Med Hyg</source>. <year>2016</year><month>Aug</month>;<volume>95</volume>(<issue>2</issue>):<fpage>394</fpage>–<lpage>400</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4269/ajtmh.15-0703</pub-id>
<?supplied-pmid 27273645?><pub-id pub-id-type="pmid">27273645</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Lyke</surname><given-names>KE</given-names></name>, <name><surname>Dabo</surname><given-names>A</given-names></name>, <name><surname>Sangare</surname><given-names>L</given-names></name>, <name><surname>Arama</surname><given-names>C</given-names></name>, <name><surname>Daou</surname><given-names>M</given-names></name>, <name><surname>Diarra</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Effects of concomitant Schistosoma haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria infection in Malian children</article-title>. <source>Infect Immun</source>. <year>2006</year><month>Oct</month>;<volume>74</volume>(<issue>10</issue>):<fpage>5718</fpage>–<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/IAI.01822-05</pub-id>
<?supplied-pmid 16988248?><pub-id pub-id-type="pmid">16988248</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Diallo</surname><given-names>TO</given-names></name>, <name><surname>Remoue</surname><given-names>F</given-names></name>, <name><surname>Gaayeb</surname><given-names>L</given-names></name>, <name><surname>Schacht</surname><given-names>AM</given-names></name>, <name><surname>Charrier</surname><given-names>N</given-names></name>, <name><surname>De Clerck</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Schistosomiasis coinfection in children influences acquired immune response against Plasmodium falciparum malaria antigens.</article-title><source>PLoS One.</source><year>2010</year><month>Sep</month><day>15</day>;<volume>5</volume>(<issue>9</issue>):<fpage>e12764</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0012764</pub-id><?supplied-pmid 20856680?><pub-id pub-id-type="pmid">20856680</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Spiegel</surname><given-names>A</given-names></name>, <name><surname>Tall</surname><given-names>A</given-names></name>, <name><surname>Raphenon</surname><given-names>G</given-names></name>, <name><surname>Trape</surname><given-names>JF</given-names></name>, <name><surname>Druilhe</surname><given-names>P</given-names></name>. <article-title>Increased frequency of malaria attacks in subjects co-infected by intestinal worms and Plasmodium falciparum malaria</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2003</year><month>Mar</month>;<volume>97</volume>(<issue>2</issue>):<fpage>198</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0035-9203(03)90117-9</pub-id>
<?supplied-pmid 14584377?><pub-id pub-id-type="pmid">14584377</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Abanyie</surname><given-names>FA</given-names></name>, <name><surname>McCracken</surname><given-names>C</given-names></name>, <name><surname>Kirwan</surname><given-names>P</given-names></name>, <name><surname>Molloy</surname><given-names>SF</given-names></name>, <name><surname>Asaolu</surname><given-names>SO</given-names></name>, <name><surname>Holland</surname><given-names>CV</given-names></name>, <etal>et al</etal>. <article-title>Ascaris co-infection does not alter malaria-induced anaemia in a cohort of Nigerian preschool children.</article-title><source>Malar J.</source><year>2013</year><month>Jan</month><day>2</day>;<volume>12</volume>:<fpage>1</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1475-2875-12-1</pub-id><?supplied-pmid 23282136?><pub-id pub-id-type="pmid">23282136</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Shapiro</surname><given-names>AE</given-names></name>, <name><surname>Tukahebwa</surname><given-names>EM</given-names></name>, <name><surname>Kasten</surname><given-names>J</given-names></name>, <name><surname>Clarke</surname><given-names>SE</given-names></name>, <name><surname>Magnussen</surname><given-names>P</given-names></name>, <name><surname>Olsen</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology of helminth infections and their relationship to clinical malaria in southwest Uganda</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2005</year><month>Jan</month>;<volume>99</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.trstmh.2004.02.006</pub-id>
<?supplied-pmid 15550257?><pub-id pub-id-type="pmid">15550257</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Dejon-Agobe</surname><given-names>JC</given-names></name>, <name><surname>Zinsou</surname><given-names>JF</given-names></name>, <name><surname>Honkpehedji</surname><given-names>YJ</given-names></name>, <name><surname>Ateba-Ngoa</surname><given-names>U</given-names></name>, <name><surname>Edoa</surname><given-names>JR</given-names></name>, <name><surname>Adegbite</surname><given-names>BR</given-names></name>, <etal>et al</etal>. <article-title>Schistosoma haematobium effects on Plasmodium falciparum infection modified by soil-transmitted helminths in school-age children living in rural areas of Gabon.</article-title><source>PLoS Negl Trop Dis.</source><year>2018</year><month>Aug</month>;<volume>12</volume>(<issue>8</issue>):<fpage>e0006663</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0006663</pub-id><?supplied-pmid 30080853?><pub-id pub-id-type="pmid">30080853</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Bruckner</surname><given-names>S</given-names></name>, <name><surname>Agnandji</surname><given-names>ST</given-names></name>, <name><surname>Berberich</surname><given-names>S</given-names></name>, <name><surname>Bache</surname><given-names>E</given-names></name>, <name><surname>Fernandes</surname><given-names>JF</given-names></name>, <name><surname>Schweiger</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial.</article-title><source>PLoS Negl Trop Dis</source>. <year>2015</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e0003768</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0003768</pub-id><?supplied-pmid 26053679?><pub-id pub-id-type="pmid">26053679</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Elias</surname><given-names>D</given-names></name>, <name><surname>Akuffo</surname><given-names>H</given-names></name>, <name><surname>Britton</surname><given-names>S</given-names></name>. <article-title>Helminthes could influence the outcome of vaccines against TB in the tropics</article-title>. <source>Parasite Immunol</source>. <year>2006</year><month>Oct</month>;<volume>28</volume>(<issue>10</issue>):<fpage>507</fpage>–<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-3024.2006.00854.x</pub-id>
<?supplied-pmid 16965286?><pub-id pub-id-type="pmid">16965286</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Elias</surname><given-names>D</given-names></name>, <name><surname>Akuffo</surname><given-names>H</given-names></name>, <name><surname>Pawlowski</surname><given-names>A</given-names></name>, <name><surname>Haile</surname><given-names>M</given-names></name>, <name><surname>Schon</surname><given-names>T</given-names></name>, <name><surname>Britton</surname><given-names>S</given-names></name>. <article-title>Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis</article-title>. <source>Vaccine</source>. <year>2005</year><month>Feb</month><day>3</day>;<volume>23</volume>(<issue>11</issue>):<fpage>1326</fpage>–<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.038</pub-id>
<?supplied-pmid 15661380?><pub-id pub-id-type="pmid">15661380</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Elias</surname><given-names>D</given-names></name>, <name><surname>Britton</surname><given-names>S</given-names></name>, <name><surname>Aseffa</surname><given-names>A</given-names></name>, <name><surname>Engers</surname><given-names>H</given-names></name>, <name><surname>Akuffo</surname><given-names>H</given-names></name>. <article-title>Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production</article-title>. <source>Vaccine</source>. <year>2008</year><month>Jul</month><day>23</day>;<volume>26</volume>(<issue>31</issue>):<fpage>3897</fpage>–<lpage>902</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.04.083</pub-id>
<?supplied-pmid 18554755?><pub-id pub-id-type="pmid">18554755</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Elias</surname><given-names>D</given-names></name>, <name><surname>Wolday</surname><given-names>D</given-names></name>, <name><surname>Akuffo</surname><given-names>H</given-names></name>, <name><surname>Petros</surname><given-names>B</given-names></name>, <name><surname>Bronner</surname><given-names>U</given-names></name>, <name><surname>Britton</surname><given-names>S</given-names></name>. <article-title>Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination.</article-title><source>Clin Exp Immunol</source>. <year>2001</year><month>Feb</month>;<volume>123</volume>(<issue>2</issue>):<fpage>219</fpage>–<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1046/j.1365-2249.2001.01446.x</pub-id>
<?supplied-pmid 11207651?><pub-id pub-id-type="pmid">11207651</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Flügge</surname><given-names>J</given-names></name>, <name><surname>Adegnika</surname><given-names>AA</given-names></name>, <name><surname>Honkpehedji</surname><given-names>YJ</given-names></name>, <name><surname>Sandri</surname><given-names>TL</given-names></name>, <name><surname>Askani</surname><given-names>E</given-names></name>, <name><surname>Manouana</surname><given-names>GP</given-names></name>, <etal>et al</etal>. <article-title>Impact of Helminth Infections during Pregnancy on Vaccine Immunogenicity in Gabonese Infants.</article-title><source>Vaccines</source>. <year>2020</year><month>Sep</month>;<volume>8</volume>(<issue>3</issue>):<fpage>381</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/vaccines8030381</pub-id><?supplied-pmid 32664597?><pub-id pub-id-type="pmid">32664597</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Malhotra</surname><given-names>I</given-names></name>, <name><surname>McKibben</surname><given-names>M</given-names></name>, <name><surname>Mungai</surname><given-names>P</given-names></name>, <name><surname>McKibben</surname><given-names>E</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Sutherland</surname><given-names>LJ</given-names></name>, <etal>et al</etal>. <article-title>Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya.</article-title><source>PLoS Negl Trop Dis.</source><year>2015</year><month>Jan</month>;<volume>9</volume>(<issue>1</issue>):<fpage>e0003466</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0003466</pub-id><?supplied-pmid 25590337?><pub-id pub-id-type="pmid">25590337</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Coelho</surname><given-names>CH</given-names></name>, <name><surname>Gazzinelli-Guimaraes</surname><given-names>PH</given-names></name>, <name><surname>Howard</surname><given-names>J</given-names></name>, <name><surname>Barnafo</surname><given-names>E</given-names></name>, <name><surname>Alani</surname><given-names>NAH</given-names></name>, <name><surname>Muratova</surname><given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel(R) in mice.</article-title><source>Vaccine</source>. <year>2019</year><month>Feb</month><day>14</day>;<volume>37</volume>(<issue>8</issue>):<fpage>1038</fpage>–<lpage>45</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.01.027</pub-id>
<?supplied-pmid 30685251?><pub-id pub-id-type="pmid">30685251</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Esen</surname><given-names>M</given-names></name>, <name><surname>Mordmuller</surname><given-names>B</given-names></name>, <name><surname>de Salazar</surname><given-names>PM</given-names></name>, <name><surname>Adegnika</surname><given-names>AA</given-names></name>, <name><surname>Agnandji</surname><given-names>ST</given-names></name>, <name><surname>Schaumburg</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura</article-title>. <source>Vaccine</source>. <year>2012</year><month>Dec</month><day>14</day>;<volume>30</volume>(<issue>52</issue>):<fpage>7621</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.026</pub-id>
<?supplied-pmid 23085365?><pub-id pub-id-type="pmid">23085365</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Noland</surname><given-names>GS</given-names></name>, <name><surname>Chowdhury</surname><given-names>DR</given-names></name>, <name><surname>Urban</surname><given-names>JF</given-names></name>, <name><surname>Zavala</surname><given-names>F</given-names></name>, <name><surname>Kumar</surname><given-names>N</given-names></name>. <article-title>Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice</article-title>. <source>Vaccine</source>. <year>2010</year><month>Apr</month><day>9</day>;<volume>28</volume>(<issue>17</issue>):<fpage>2917</fpage>–<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.055</pub-id>
<?supplied-pmid 20188676?><pub-id pub-id-type="pmid">20188676</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Su</surname><given-names>Z</given-names></name>, <name><surname>Segura</surname><given-names>M</given-names></name>, <name><surname>Stevenson</surname><given-names>MM</given-names></name>. <article-title>Reduced Protective Efficacy of a Blood-Stage Malaria Vaccine by Concurrent Nematode Infection</article-title>. <source>Infect Immun</source>. <year>2006</year><month>Apr</month><day>1</day>;<volume>74</volume>(<issue>4</issue>):<fpage>2138</fpage>–<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/IAI.74.4.2138-2144.2006</pub-id>
<?supplied-pmid 16552043?><pub-id pub-id-type="pmid">16552043</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Theisen</surname><given-names>M</given-names></name>, <name><surname>Soe</surname><given-names>S</given-names></name>, <name><surname>Brunstedt</surname><given-names>K</given-names></name>, <name><surname>Follmann</surname><given-names>F</given-names></name>, <name><surname>Bredmose</surname><given-names>L</given-names></name>, <name><surname>Israelsen</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies</article-title>. <source>Vaccine</source>. <year>2004</year><month>Mar</month><day>12</day>;<volume>22</volume>(<issue>9–10</issue>):<fpage>1188</fpage>–<lpage>98</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.09.017</pub-id>
<?supplied-pmid 15003647?><pub-id pub-id-type="pmid">15003647</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Belard</surname><given-names>S</given-names></name>, <name><surname>Issifou</surname><given-names>S</given-names></name>, <name><surname>Hounkpatin</surname><given-names>AB</given-names></name>, <name><surname>Schaumburg</surname><given-names>F</given-names></name>, <name><surname>Ngoa</surname><given-names>UA</given-names></name>, <name><surname>Esen</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.</article-title><source>PLoS One.</source><year>2011</year>;<volume>6</volume>(<issue>7</issue>):<fpage>e22525</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0022525</pub-id><?supplied-pmid 21829466?><pub-id pub-id-type="pmid">21829466</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Esen</surname><given-names>M</given-names></name>, <name><surname>Kremsner</surname><given-names>PG</given-names></name>, <name><surname>Schleucher</surname><given-names>R</given-names></name>, <name><surname>Gassler</surname><given-names>M</given-names></name>, <name><surname>Imoukhuede</surname><given-names>EB</given-names></name>, <name><surname>Imbault</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Safety and immunogenicity of GMZ2—a MSP3-GLURP fusion protein malaria vaccine candidate</article-title>. <source>Vaccine</source>. <year>2009</year><month>Nov</month><day>16</day>;<volume>27</volume>(<issue>49</issue>):<fpage>6862</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.09.011</pub-id>
<?supplied-pmid 19755144?><pub-id pub-id-type="pmid">19755144</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Mordmuller</surname><given-names>B</given-names></name>, <name><surname>Szywon</surname><given-names>K</given-names></name>, <name><surname>Greutelaers</surname><given-names>B</given-names></name>, <name><surname>Esen</surname><given-names>M</given-names></name>, <name><surname>Mewono</surname><given-names>L</given-names></name>, <name><surname>Treut</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon.</article-title><source>Vaccine</source>. <year>2010</year><month>Sep</month><day>24</day>;<volume>28</volume>(<issue>41</issue>):<fpage>6698</fpage>–<lpage>703</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.07.085</pub-id>
<?supplied-pmid 20696154?><pub-id pub-id-type="pmid">20696154</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Dejon-Agobe</surname><given-names>JC</given-names></name>, <name><surname>Ateba-Ngoa</surname><given-names>U</given-names></name>, <name><surname>Lalremruata</surname><given-names>A</given-names></name>, <name><surname>Homoet</surname><given-names>A</given-names></name>, <name><surname>Engelhorn</surname><given-names>J</given-names></name>, <name><surname>Nouatin</surname><given-names>OP</given-names></name>, <etal>et al</etal>. <article-title>Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2</article-title>. <source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>2019</year><month>Sep</month><day>27</day>;<volume>69</volume>(<issue>8</issue>):<fpage>1377</fpage>–<lpage>84</lpage>.</mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Dejon-Agobé</surname><given-names>JC</given-names></name>, <name><surname>Honkpehedji</surname><given-names>YJ</given-names></name>, <name><surname>Zinsou</surname><given-names>JF</given-names></name>, <name><surname>Edoa</surname><given-names>JR</given-names></name>, <name><surname>Adégbitè</surname><given-names>BR</given-names></name>, <name><surname>Mangaboula</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology of Schistosomiasis and Soil-Transmitted Helminth Coinfections among Schoolchildren Living in Lambaréné, Gabon</article-title>. <source>Am J Trop Med Hyg</source>. <year>2020</year><month>May</month><day>18</day>;<volume>103</volume>(<issue>1</issue>):<fpage>325</fpage>–<lpage>33</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4269/ajtmh.19-0835</pub-id>
<?supplied-pmid 32431272?><pub-id pub-id-type="pmid">32431272</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Dejon-Agobé</surname><given-names>JC</given-names></name>, <name><surname>Edoa</surname><given-names>JR</given-names></name>, <name><surname>Honkpehedji</surname><given-names>YJ</given-names></name>, <name><surname>Zinsou</surname><given-names>JF</given-names></name>, <name><surname>Adégbitè</surname><given-names>BR</given-names></name>, <name><surname>Ngwese</surname><given-names>MM</given-names></name>, <etal>et al</etal>. <article-title>Schistosoma haematobium infection morbidity, praziquantel effectiveness and reinfection rate among children and young adults in Gabon.</article-title><source>Parasit Vectors.</source><year>2019</year><month>Dec</month><day>10</day>;<volume>12</volume>(<issue>1</issue>):<fpage>577</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13071-019-3836-6</pub-id><?supplied-pmid 31823806?><pub-id pub-id-type="pmid">31823806</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Borrmann</surname><given-names>S</given-names></name>, <name><surname>Szlezák</surname><given-names>N</given-names></name>, <name><surname>Faucher</surname><given-names>J-F</given-names></name>, <name><surname>Matsiegui</surname><given-names>P-B</given-names></name>, <name><surname>Neubauer</surname><given-names>R</given-names></name>, <name><surname>Binder</surname><given-names>RK</given-names></name>, <etal>et al</etal>. <article-title>Artesunate and Praziquantel for the Treatment of Schistosoma haematobium Infections: A Double-Blind, Randomized, Placebo-Controlled Study</article-title>. <source>J Infect Dis</source>. <year>2001</year><month>Nov</month><day>15</day>;<volume>184</volume>(<issue>10</issue>):<fpage>1363</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/324004</pub-id>
<?supplied-pmid 11679932?><pub-id pub-id-type="pmid">11679932</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Dal-Bianco</surname><given-names>MP</given-names></name>, <name><surname>Koster</surname><given-names>KB</given-names></name>, <name><surname>Kombila</surname><given-names>UD</given-names></name>, <name><surname>Kun</surname><given-names>JF</given-names></name>, <name><surname>Grobusch</surname><given-names>MP</given-names></name>, <name><surname>Ngoma</surname><given-names>GM</given-names></name>, <etal>et al</etal>. <article-title>High prevalence of asymptomatic Plasmodium falciparum infection in Gabonese adults</article-title>. <source>Am J Trop Med Hyg</source>. <year>2007</year><month>Nov</month>;<volume>77</volume>(<issue>5</issue>):<fpage>939</fpage>–<lpage>42</lpage>. <?supplied-pmid 17984357?><pub-id pub-id-type="pmid">17984357</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Katz</surname><given-names>N</given-names></name>, <name><surname>Chaves</surname><given-names>A</given-names></name>, <name><surname>Pellegrino</surname><given-names>J</given-names></name>. <article-title>A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni.</article-title><source>Rev Inst Med Trop Sao Paulo.</source><year>1972</year><month>Dec</month>;<volume>14</volume>(<issue>6</issue>):<fpage>397</fpage>–<lpage>400</lpage>. <?supplied-pmid 4675644?><pub-id pub-id-type="pmid">4675644</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Mbong Ngwese</surname><given-names>M</given-names></name>, <name><surname>Prince Manouana</surname><given-names>G</given-names></name>, <name><surname>Nguema Moure</surname><given-names>PA</given-names></name>, <name><surname>Ramharter</surname><given-names>M</given-names></name>, <name><surname>Esen</surname><given-names>M</given-names></name>, <name><surname>Adégnika</surname><given-names>AA</given-names></name>. <article-title>Diagnostic Techniques of Soil-Transmitted Helminths: Impact on Control Measures</article-title>. <source>Trop Med Infect Dis</source> [Internet]. <year>2020</year>
<month>Jun</month>
<day>5</day>;<volume>5</volume>(<issue>2</issue>). <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/tropicalmed5020093</pub-id>
<?supplied-pmid 32516900?><pub-id pub-id-type="pmid">32516900</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Akue</surname><given-names>JP</given-names></name>, <name><surname>Nkoghe</surname><given-names>D</given-names></name>, <name><surname>Padilla</surname><given-names>C</given-names></name>, <name><surname>Moussavou</surname><given-names>G</given-names></name>, <name><surname>Moukana</surname><given-names>H</given-names></name>, <name><surname>Mbou</surname><given-names>RA</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology of Concomitant Infection Due to Loa loa and Mansonella perstans in Gabon.</article-title><source>PLoS Negl Trop Dis</source> [Internet]. <year>2011</year>
<month>Oct</month>
<day>11</day>;<volume>5</volume>(<issue>10</issue>). <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0001329</pub-id>
<?supplied-pmid 22022623?><pub-id pub-id-type="pmid">22022623</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Kaisar</surname><given-names>MMM</given-names></name>, <name><surname>Brienen</surname><given-names>EAT</given-names></name>, <name><surname>Djuardi</surname><given-names>Y</given-names></name>, <name><surname>Sartono</surname><given-names>E</given-names></name>, <name><surname>Yazdanbakhsh</surname><given-names>M</given-names></name>, <name><surname>Verweij</surname><given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>Improved diagnosis of Trichuris trichiura by using a bead-beating procedure on ethanol preserved stool samples prior to DNA isolation and the performance of multiplex real-time PCR for intestinal parasites</article-title>. <source>Parasitology</source>. <year>2017</year><month>Jun</month>;<volume>144</volume>(<issue>7</issue>):<fpage>965</fpage>–<lpage>74</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1017/S0031182017000129</pub-id>
<?supplied-pmid 28290266?><pub-id pub-id-type="pmid">28290266</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Verweij</surname><given-names>JJ</given-names></name>, <name><surname>Brienen</surname><given-names>EA</given-names></name>, <name><surname>Ziem</surname><given-names>J</given-names></name>, <name><surname>Yelifari</surname><given-names>L</given-names></name>, <name><surname>Polderman</surname><given-names>AM</given-names></name>, <name><surname>Van Lieshout</surname><given-names>L</given-names></name>. <article-title>Simultaneous detection and quantification of Ancylostoma duodenale, Necator americanus, and Oesophagostomum bifurcum in fecal samples using multiplex real-time PCR</article-title>. <source>Am J Trop Med Hyg</source>. <year>2007</year><month>Oct</month>;<volume>77</volume>(<issue>4</issue>):<fpage>685</fpage>–<lpage>90</lpage>. <?supplied-pmid 17978072?><pub-id pub-id-type="pmid">17978072</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Verweij</surname><given-names>JJ</given-names></name>, <name><surname>Canales</surname><given-names>M</given-names></name>, <name><surname>Polman</surname><given-names>K</given-names></name>, <name><surname>Ziem</surname><given-names>J</given-names></name>, <name><surname>Brienen</surname><given-names>EA</given-names></name>, <name><surname>Polderman</surname><given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Molecular diagnosis of Strongyloides stercoralis in faecal samples using real-time PCR</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2009</year><month>Apr</month>;<volume>103</volume>(<issue>4</issue>):<fpage>342</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.trstmh.2008.12.001</pub-id>
<?supplied-pmid 19195671?><pub-id pub-id-type="pmid">19195671</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Gratz</surname><given-names>J</given-names></name>, <name><surname>Amour</surname><given-names>C</given-names></name>, <name><surname>Kibiki</surname><given-names>G</given-names></name>, <name><surname>Becker</surname><given-names>S</given-names></name>, <name><surname>Janaki</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogens</article-title>. <source>J Clin Microbiol</source>. <year>2013</year><month>Feb</month>;<volume>51</volume>(<issue>2</issue>):<fpage>472</fpage>–<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JCM.02658-12</pub-id>
<?supplied-pmid 23175269?><pub-id pub-id-type="pmid">23175269</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Taniuchi</surname><given-names>M</given-names></name>, <name><surname>Verweij</surname><given-names>JJ</given-names></name>, <name><surname>Noor</surname><given-names>Z</given-names></name>, <name><surname>Sobuz</surname><given-names>SU</given-names></name>, <name><surname>Lieshout</surname><given-names>L</given-names></name>, <name><surname>Petri</surname><given-names>WA</given-names><suffix>Jr</suffix></name>, <etal>et al</etal>. <article-title>High throughput multiplex PCR and probe-based detection with Luminex beads for seven intestinal parasites</article-title>. <source>Am J Trop Med Hyg</source>. <year>2011</year><month>Feb</month>;<volume>84</volume>(<issue>2</issue>):<fpage>332</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4269/ajtmh.2011.10-0461</pub-id>
<?supplied-pmid 21292910?><pub-id pub-id-type="pmid">21292910</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Adegnika</surname><given-names>AA</given-names></name>, <name><surname>Ramharter</surname><given-names>M</given-names></name>, <name><surname>Agnandji</surname><given-names>ST</given-names></name>, <name><surname>Ateba Ngoa</surname><given-names>U</given-names></name>, <name><surname>Issifou</surname><given-names>S</given-names></name>, <name><surname>Yazdanbahksh</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology of parasitic co-infections during pregnancy in Lambarene, Gabon.</article-title><source>Trop Med Int Health</source>. <year>2010</year><month>Oct</month>;<volume>15</volume>(<issue>10</issue>):<fpage>1204</fpage>–<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1365-3156.2010.02598.x</pub-id>
<?supplied-pmid 20636299?><pub-id pub-id-type="pmid">20636299</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Verroust</surname><given-names>PJ</given-names></name>, <name><surname>Adam</surname><given-names>C</given-names></name>, <name><surname>Smith</surname><given-names>MD</given-names></name>, <name><surname>Richard-Lenoble</surname><given-names>D</given-names></name>, <name><surname>Kourilsky</surname><given-names>O</given-names></name>, <name><surname>Morel-Maroger</surname><given-names>LJ</given-names></name>. <article-title>Circulating immune complexes and C3d in human parasitosis</article-title>. <source>Kidney Int</source>. <year>1979</year><month>Jul</month>;<volume>16</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ki.1979.97</pub-id>
<?supplied-pmid 575177?><pub-id pub-id-type="pmid">575177</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Dempsey</surname><given-names>PW</given-names></name>, <name><surname>Allison</surname><given-names>ME</given-names></name>, <name><surname>Akkaraju</surname><given-names>S</given-names></name>, <name><surname>Goodnow</surname><given-names>CC</given-names></name>, <name><surname>Fearon</surname><given-names>DT</given-names></name>. <article-title>C3d of complement as a molecular adjuvant: bridging innate and acquired immunity</article-title>. <source>Science</source>. <year>1996</year><month>Jan</month><day>19</day>;<volume>271</volume>(<issue>5247</issue>):<fpage>348</fpage>–<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.271.5247.348</pub-id>
<?supplied-pmid 8553069?><pub-id pub-id-type="pmid">8553069</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Luoni</surname><given-names>G</given-names></name>, <name><surname>Verra</surname><given-names>F</given-names></name>, <name><surname>Arca</surname><given-names>B</given-names></name>, <name><surname>Sirima</surname><given-names>BS</given-names></name>, <name><surname>Troye-Blomberg</surname><given-names>M</given-names></name>, <name><surname>Coluzzi</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Antimalarial antibody levels and IL4 polymorphism in the Fulani of West Africa</article-title>. <source>Genes Immun</source>. <year>2001</year><month>Nov</month>;<volume>2</volume>(<issue>7</issue>):<fpage>411</fpage>–<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.gene.6363797</pub-id>
<?supplied-pmid 11704810?><pub-id pub-id-type="pmid">11704810</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Tokplonou</surname><given-names>L</given-names></name>, <name><surname>Nouatin</surname><given-names>O</given-names></name>, <name><surname>Sonon</surname><given-names>P</given-names></name>, <name><surname>M’po</surname><given-names>G</given-names></name>, <name><surname>Glitho</surname><given-names>S</given-names></name>, <name><surname>Agniwo</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Schistosoma haematobium infection modulates Plasmodium falciparum parasite density and antimalarial antibody responses</article-title>. <source>Parasite Immunol</source>. <year>2020</year><month>Feb</month><day>5</day>;<fpage>e12702</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/pim.12702</pub-id><?supplied-pmid 32020650?><pub-id pub-id-type="pmid">32020650</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Anuradha</surname><given-names>R</given-names></name>, <name><surname>Munisankar</surname><given-names>S</given-names></name>, <name><surname>Bhootra</surname><given-names>Y</given-names></name>, <name><surname>Dolla</surname><given-names>C</given-names></name>, <name><surname>Kumaran</surname><given-names>P</given-names></name>, <name><surname>Nutman</surname><given-names>TB</given-names></name>, <etal>et al</etal>. <article-title>Modulation of Mycobacterium tuberculosis-specific humoral immune responses is associated with Strongyloides stercoralis co-infection.</article-title><source>PLoS Negl Trop Dis.</source><year>2017</year><month>May</month>;<volume>11</volume>(<issue>5</issue>):<fpage>e0005569</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0005569</pub-id><?supplied-pmid 28459817?><pub-id pub-id-type="pmid">28459817</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Iriemenam</surname><given-names>NC</given-names></name>, <name><surname>Sanyaolu</surname><given-names>AO</given-names></name>, <name><surname>Oyibo</surname><given-names>WA</given-names></name>, <name><surname>Fagbenro-Beyioku</surname><given-names>AF</given-names></name>. <article-title>Strongyloides stercoralis and the immune response</article-title>. <source>Parasitol Int</source>. <year>2010</year><month>Mar</month>;<volume>59</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.parint.2009.10.009</pub-id>
<?supplied-pmid 19892034?><pub-id pub-id-type="pmid">19892034</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>Bouharoun-Tayoun</surname><given-names>H</given-names></name>, <name><surname>Attanath</surname><given-names>P</given-names></name>, <name><surname>Sabchareon</surname><given-names>A</given-names></name>, <name><surname>Chongsuphajaisiddhi</surname><given-names>T</given-names></name>, <name><surname>Druilhe</surname><given-names>P</given-names></name>. <article-title>Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes</article-title>. <source>J Exp Med</source>. <year>1990</year><month>Dec</month><day>1</day>;<volume>172</volume>(<issue>6</issue>):<fpage>1633</fpage>–<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1084/jem.172.6.1633</pub-id>
<?supplied-pmid 2258697?><pub-id pub-id-type="pmid">2258697</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>O’Donnell</surname><given-names>RA</given-names></name>, <name><surname>de Koning-Ward</surname><given-names>TF</given-names></name>, <name><surname>Burt</surname><given-names>RA</given-names></name>, <name><surname>Bockarie</surname><given-names>M</given-names></name>, <name><surname>Reeder</surname><given-names>JC</given-names></name>, <name><surname>Cowman</surname><given-names>AF</given-names></name>, <etal>et al</etal>. <article-title>Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.</article-title><source>J Exp Med</source>. <year>2001</year><month>Jun</month><day>18</day>;<volume>193</volume>(<issue>12</issue>):<fpage>1403</fpage>–<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1084/jem.193.12.1403</pub-id>
<?supplied-pmid 11413195?><pub-id pub-id-type="pmid">11413195</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref049">
                <label>49</label>
                <mixed-citation publication-type="journal"><name><surname>Druilhe</surname><given-names>P</given-names></name>, <name><surname>Tall</surname><given-names>A</given-names></name>, <name><surname>Sokhna</surname><given-names>C</given-names></name>. <article-title>Worms can worsen malaria: towards a new means to roll back malaria?</article-title><source>Trends Parasitol</source>. <year>2005</year><month>Aug</month>;<volume>21</volume>(<issue>8</issue>):<fpage>359</fpage>–<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.pt.2005.06.011</pub-id>
<?supplied-pmid 15967721?><pub-id pub-id-type="pmid">15967721</pub-id></mixed-citation>
              </ref>
              <ref id="pntd.0009361.ref050">
                <label>50</label>
                <mixed-citation publication-type="journal"><name><surname>Roussilhon</surname><given-names>C</given-names></name>, <name><surname>Brasseur</surname><given-names>P</given-names></name>, <name><surname>Agnamey</surname><given-names>P</given-names></name>, <name><surname>Perignon</surname><given-names>JL</given-names></name>, <name><surname>Druilhe</surname><given-names>P</given-names></name>. <article-title>Understanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms.</article-title><source>PLoS One.</source><year>2010</year><month>Feb</month><day>19</day>;<volume>5</volume>(<issue>2</issue>):<fpage>e9309</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0009309</pub-id><?supplied-pmid 20174576?><pub-id pub-id-type="pmid">20174576</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
